University of South Florida

USF Pharmacy gets grant from CoreRx and Florida High Tech Corridor to train students in pharmaceutical industry innovation

Tampa, FL (June 24, 2013) – The University of South Florida College of Pharmacy received a $195,000 grant  from CoreRx, Inc., a research-based drug development firm, and the Florida High Tech Corridor to bolster the training needed to prepare students for innovation and technology in the pharmaceutical industry.

USF’s existing partnership with CoreRx  offers the university’s Doctor of Pharmacy (PharmD) students some internships with hands-on training and teaching by CoreRX scientists. The new funds from CoreRx (including in-kind contributions) and the Florida High Tech Corridor will allow additional qualified USF students across disciplines — from doctoral and graduate to undergraduate levels — to learn firsthand about the industry’s drug-making and delivery process.

IMG_5424_RSS

L to R: USF College of Pharmacy’s Dr. Srinivas Tipparaju, principal investigator for the Florida High Tech Corridor grant; with co-investigator Dr. Yashwant Pathak; Dr. Todd Daviau, president and CEO of CoreRx; and Dr. Kevin Sneed, dean of the USF College of Pharmacy.

The academic-industry alliance helps address the state’s need for a more highly skilled workforce prepared for STEM (science, technology, engineering, math) jobs, said Srinivas Tipparaju, PhD, MPharm, assistant professor of pharmaceutical sciences at USF Health.  

Dr. Tipparaju is principal investigator for the Florida High Tech Corridor grant, and Yashwant Pathak, PhD, MPharm, associate dean in the USF College of Pharmacy, is co-investigator. They are working with the CoreRx team led by Todd R. Daviau, president and CEO of CoreRx.

“There is a shortage of home-grown talent to meet the workforce demands of the technology-driven, multibillion-dollar pharmaceutical sector,” Dr. Tipparaju said.  “We want to create that talent right here in the Tampa Bay area, so that our graduates can take leading roles managing and delivering advanced pharmaceutical care in tomorrow’s patient-centered practice, as well as help drive pharmaceutical research and development.”

“We’re thrilled to expand our affiliation with USF and to continue to find ways to offer students hands-on learning experiences in industrial pharmaceutics,” Dr. Daviau said. “We are excited that CoreRx will play a role in furthering the development of more students through this opportunity.”

Brian Formulations 1[3]_RSS

Brian McMillan, MSPharm, vice president of formulations for CoreRx, helped lead first-year USF pharmacy students on a tour of the company’s laboratories earlier this year.

Tablet Press[3]_RSS

McMillan, far right, demonstrates the tablet press, a mechanical device that compresses powder into drug tablets of uniform size and weight.

Students will work on real-world projects with the teaching and guidance of CoreRx scientists who are USF visiting faculty members.

Among the key concepts students will learn will be early-stage development of pharmaceuticals, how liquid medicine, tablets and capsules are made (with hands-on instruction), the functionality of additional ingredients found in modern-day drugs, and  hands-on processes used to manufacture a wide range of pharmaceutical dosage forms.  In addition, the training will help educate students about biopharmaceutical techniques, quality control and assurance, and the U.S. Food and Drug Administration’s regulatory standards for prescription drugs.

USF’s newest college, the College of Pharmacy, admitted it first class less than two years ago and continues to advance on a fast track. The program, awarded candidate accreditation status by the Accreditation Council for Pharmacy Education, attracted nearly 800 applicants for 100 spots in the class entering August 2013.

-About USF Health-

USF Health’s mission is to envision and implement the future of health. It is the partnership of the USF Health Morsani College of Medicine, the College of Nursing, the College of Public Health, the College of Pharmacy, the School of Biomedical Sciences and the School of Physical Therapy and Rehabilitation Sciences; and the USF Physician’s Group. The University of South Florida is a global research university ranked 50th in the nation by the National Science Foundation for both federal and total research expenditures among all U.S. universities. For more information, visit www.health.usf.edu

About CoreRx, Inc.

CoreRx is a contract research organization providing customized pre-formulation services, formulation development, manufacturing, and analytical services to pharmaceutical, biotechnology, academic, and veterinary clients. The company is renowned for reliably expediting early development activities to speed potential drugs to clinical trials while applying stage-specific scientific knowledge and experience. CoreRx’s unique corporate structure creates project teams that work intensively with each client, bringing an extension of its own organization into the CoreRx lab.

Keep on top of new developments at CoreRx and throughout the drug development industry by following www.twitter.com/CoreRx  and for more detailed information about the company, visit www.corerxpharma.com

Media contacts:
Anne DeLotto Baier, USF Health Communications, (813) 974-3303 or abaier@health.usf.edu
Jenna Leitao, CoreRX Inc.,   (727) 259-6950 or  jenna.leitao@corerxpharma.com

V Blender_600x400

USF pharmacy students stand next to a V-blender used to mix active pharmaceutical ingredients with pharmacologically inactive substances. The are gowned to comply with current Good Manufacturing Practices, the FDA’s regulations to ensure the quality of drug products.

 Group Outside[3]_RSS

Photos by Jenna Leitao, CoreRx Inc.

 

.

Network-wide options by YD - Freelance Wordpress Developer